1. Prof Lukman.pdf
-
Upload
knigk-templar -
Category
Documents
-
view
29 -
download
3
description
Transcript of 1. Prof Lukman.pdf
Prof .Prof .DR.drDR.dr LukmanLukman H.Makmun,SpPDH.Makmun,SpPD--KKV,KgerKKV,KgerLahat,03Lahat,03 MaretMaret 19471947
Riwayat Pendidikan:FKUI Tahun 1971Internis Tahun 1979Konsultasi Kardiologi FKUI Tahun 1984Konsultan Geriatri FKUI Tahun 2000
Jabatan:2001-2004 Ketua Devisi Geriatri FKUI RSCM2008-2011 Ketua Devisi Kardiologi Departemen Penyakit Dalam FKUI2008-2011 Ketua Departemen Pendidikan Kedokteran FKUI
Jabatan Saat ini: Guru Besar FKUI
Organisasi: Ketua Umum PB IKKI
Novel Oral Anti Coagulant forStroke Prevention in Atrial
Fibrillation Patient.
Lukman H.MakmunDiv.Kardiologi Dept.I.Peny.Dalam
FKUI/RSCM
Content review:• Epidemiology AF and Stroke• Scoring stroke risk in AF• Coagulation cascade and thrombin
formation• Effect mechanism of anti platelet and anti
thrombotic drug.• Treatment guidelines for AF.• New oral anti coagulant.• Rocket study
The number of patients with AF isanticipated to continue to increase
41. Miyasaka Y et al, 2006; 2. Go AS et al, 2001.
Year
2.08 2.442.26
5.1
5.1
0
2
4
6
8
10
12
14
16
1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050
Patie
nts
with
AF
(mill
ions
)
5.42
11.7
15.2
4.34
9.4
11.7
3.33
7.5
8.9
2.94
6.8
7.78.4
10.2
3.804.78
10.3
13.1
5.16
11.1
14.3
5.61
12.1
15.9
5.6
5.9
2.66
6.1
6.7
Olmsted County Data, 20061
(assuming a continued increase in AF incidence)
ATRIA Study Data, 20002
Olmsted County Data, 20061
(assuming no further increase in AF incidence)
Stroke is a frequent & serious complication of AF
• AF is the leading cause of embolic stroke4
• AF is associated with a 5-fold higher stroke risk overall1
• Without preventive treatment, each year approximately 1in 20 patients with AF will have a stroke3
• AF stroke is usually more severe than stroke due toother causes1
• The mortality rate for patients with AF is double that inpeople with normal heart rhythm4
1. Savelieva I et al. Ann Med 2007;39:371–91; 2. Fuster V et al. European Heart Journal 2006;27:1979–2030;3. Atrial Fibrillation Investigators. Arch Intern Med 1994;154:1449–57;4. Benjamin EJ et al. Circulation 1998;98:946–52
6
Patients with AF have an ~fivefoldincreased risk of ischaemic stroke
2-ye
ar a
ge-a
djus
ted
inci
denc
eof
str
oke/
1,00
0 in
divi
dual
s
Individualswith AF
Individualswithout AF
Risk ratio=4.8p<0.001
0
10
20
30
40
50
60
Framingham Heart Study (N=5,070)
Wolf PA et al, 1991. 6
CHADS2 risk stratification for stroke prevention inpatients with AF
• CHF +1• Hypertension +1• Age >75 years +1• Diabetes mellitus +1• Prior Stroke or TIA +2
• CHADS2 does not consider all risk factors: stroke riskmay be underestimated
Gage et al, 2001; 2004; Fuster et al, 2006; Singer et al, 2008
Risk category Score
Low 0
Intermediate 1
High 2
1.9 2.84
5.98.5
12.5
18.2
0
5
10
15
20
0 1 2 3 4 5 6
Stro
ke ra
te (%
per
yea
r)
n=120 n=463 n=523 n=337 n=220 n=65 n=5CHADS2 Score
AHA / ACC / ESC Guidelines EHJ 2006;27:1979–2030
Stroke risk in AF using the CHADS2score
C – CHF 1H – Hypertension 1A - Age > 75 1D - Diabetes mellitus 1S2 - TIA/Stroke 2
CHA2DS2-VASc score
Risk factor PointsCongestive heart failure/LV dysfunction +1Hypertension +1Age 75 years +2Diabetes mellitus +1Stroke/TIA/TE +2Vascular disease (MI, aortic plaque, PAD)* +1Age 65–74 years +1Sex category (female) +1Cumulative score Range 0 9
Lip et al, 2010
Score: 0 = low risk; 1 = intermediate risk; 2 = high risk
Left: MS, AF, LA enlargement; Right: Sludge in LAA that can form thrombus.(Siglow et al. TEE. Thieme Verlag. 1993)
Multiple small thrombusSiglow et al. TEE. Thieme Verlag. 1993)
Fuster V et al. Circulation 2006;114:e257–354
Treatment goals of atrial fibrillation
• Key goals of AF management :1.Prevention of thromboembolism and stroke2.Restoration & maintenance of sinus rhythm3.Control of heart rate
• Anticoagulant therapy is recommendedfor all patients regardless of the level ofstroke risk, other than those with lone AFor contra-indications to anticoagulanttherapy
AggregationAggregationof platelets intoof platelets into
a thrombusa thrombus
PlateletsPlatelets
Endothelial cellsEndothelial cells
Subendothelial spaceSubendothelial space
Platelets adheringPlatelets adheringto subendothelialto subendothelialspacespace
PlateletPlateletthrombusthrombus
Platelet Adhesion andActivation
Normal plateletsNormal plateletsin flowing bloodin flowing blood
Platelets adhering toPlatelets adhering todamaged endotheliumdamaged endothelium
and undergoingand undergoingactivationactivation
7
Platelets in Initiation of Thrombus Formation
Von Willebrand factorVon Willebrand factor
Gp IIb/IIIa complexGp IIb/IIIa complex
PlateletPlateletFibrinogenFibrinogen
FibrinogenFibrinogen
SD3321 03/12/98
SlideE972095A 15
SD33157/15/98
SlideE972095A 16
SD33157/15/98
LMWH
LMWH
Antiplatelet Agents
• Thromboxane A2 inhibitor– Acetylsalicylic acid (ASA)
• Phosphodiesterase inhibitor– Dipyridamole
• Glycoprotein (GP) IIb/IIIa blockers– Parenteral: abciximab, eptifibatide, tirofiban
• ADP-receptor antagonists– Clopidogrel– Ticlopidine
Cilostazol
SlideE972095A 19
SD33157/15/98
Platelets and Prevention ofPlatelets and Prevention ofAtherothrombosisAtherothrombosis
Platelets play a central role in thrombusPlatelets play a central role in thrombusformationformation
Initiate thrombus formation on atheroscleroticInitiate thrombus formation on atheroscleroticplaqueplaque
Platelet aggregation inhibitors inhibit formationPlatelet aggregation inhibitors inhibit formationof plateletof platelet--rich thrombi on disrupted plaquerich thrombi on disrupted plaque
Prevention of thrombus formation can preventPrevention of thrombus formation can preventacute cardiovascular ischemic events: e.g.,acute cardiovascular ischemic events: e.g.,myocardial infarction,myocardial infarction, ischemic strokeischemic stroke, and, andvascular deathvascular death
Current antithrombotic agentsCurrent antithrombotic agents
1. Rosenberg RD, Aird WC. N Engl J Med 1999;340:1555–64.2. Hirsh J, et al. Chest 1995;108 Suppl:258–75S.
3. Samama CM et al. Thromb Haemost July 2001;ISTH Abstract OC2343.4. Hirsh J, Fuster V. Circulation 1994 ;89:1469–80.5. Hirsh J, Fuster V. Circulation 1994 ;89:1449–68.
TF: tissue factorPL: phospholipidTFPI: tissue factor pathway inhibitorPS: protein SPC: protein CPCa: activated protein CTM: thrombomodulinATIII: antithrombin III
Clot
Intrinsic Pathway Extrinsic Pathway
TF
Ca2+
Xa X
II
IX
XI
XII XIIa
FibrinFibrinogen
XaVa
PLCa2+
IIa
VII
Heparin
Vitamin Kantagonists
XIa VIIa
VIIIaCa2+
PL
IXa
Fondaparinux
Direct thrombininhibitron
Key Steps in Coagulation PathwayKey Steps in Coagulation Pathway
Inhibition of one moleculeof factor Xa can inhibit thegeneration of 50 moleculesof thrombin2
Intrinsic pathway Extrinsic pathway
1. Rosenberg RD, Aird WC. N Engl J Med 1999;340(20):1555–64.2. Wessler S, Yin ET. Thrombo Diath Haemorrh 1974;32(1):71–8.
Intrinsic pathway
1
50
Xa X
II
FibrinFibrinogen
Clot
XaVa
PLCa2+
IIa
VIIIaCa2+
PL
IXa
SlideE972095A 22
SD33157/15/98
Unfractionated heparin:
- campuran molekul glycosaminoglycan- 40.000 dalton- mekanisme kerja: mengkatalysis AT III untuk
menghambat factor IIa (thrombin), F.IXa,Xa,Xia,XIIa
- mengikat sel endotel- adsorbsi s.c. kurang baik.
SlideE972095A 23
SD33157/15/98
LMWH:
- 4500 Dalton- depolymerisasi molekul unfractionated heparinMekanisme kerja: sama seperti UH- inhibisi trombin lebih lemah- anti Xa- Dual action: - inhibisi prothrombinase (F.Xa-Ca-
phospholipidV)- inaktivasi trombin langsung.
- Tidak berefek pada fungsi platelet- Afinitas lemah terhadap sel endotel- Efek hemoragik lebih sedikit- Availabilitas dengan s.c. tinggi
Anticoagulants in development havesingle targets
Adapted from Spyropoulos AC et al. Expert Opin Investig Drugs 2007;16:431–440
Clot formation
Initiation
Propagation
X
IXa
IIaThrombin
Xa
Fibrinogen Fibrin
Prothrombin
VIIa
IX
II
TF
AT
IndirectFondaparinux
DirectRivaroxaban
ApixabanEdoxabanBetrixabanDarexaban
DirectLepirudin
BivalirudinArgatrobanDabigatranTGN-167
Inactive factor
Active factor
Transformation
Catalysis
25
IIa ThrombinII
Fibrinogen Fibrin clot
FXa
Direct and indirect factor Xa (FXa) inhibition
Adapted from Turpie AG et al. N Engl J Med 2001;344:619–25
ATAT AT
Indirect factor Xainhibitor
FXa
Direct factorXa inhibitor
INDIRECTBinds to antithrombin (AT)and potentiates the activity of ATagainst FXa(e.g. idraparinux, SSR 126517)
DIRECTBinds directly to the active site of FXa,blocking substrate interactions(e.g. apixaban, rivaroxaban,edoxaban, betrixaban)
Treatment guidelines for SPAF
evidence and recommendations
Guideline recommendations ESC 2010
• Major risk factors:– Previous stroke, TIA or systemic
embolism– Age 75 years
• Clinically relevent non-major riskfactors:
– Heart failure or moderate tosevere LV systolic dysfunction(e.g. LV EF < 40%)
– Hypertension– Diabetes mellitus– Female sex– Age 65–74 years– Vascular disease
Camm et al, 2010
OAC is the preferred treatment for all patients with at leastone CHA2DS2-VASc risk factor
ACC/AHA/ESC risk stratification
• Low risk‘Lone’ AF (no other risk factors)
• Moderate riskOnly one of: age 75 years, hypertension, heart failure, LVEF 35%or diabetes mellitus
• High riskPrior thromboembolism (stroke, TIA, systemic embolism) orRheumatic mitral stenosis orProsthetic heart valve or2 of the following: age 75 years, hypertension, heart failure,
LVEF 35% or diabetes mellitus
Fuster et al. Circulation 2006
Guidelines: stroke prevention in AF
Riskcategory
Guideline recommendationsACC/AHA/ESC1 ACCP2
Low ASA (81–325 mg/day) ASA (75–325 mg/day)Moderate Oral VKA
target INR 2.5 (range 2–3)or
ASA (81–325 mg/day)
Oral VKAtarget INR 2.5 (range 2–3)
orASA (75–325 mg/day)
High risk Oral VKAtarget INR 2.5 (range 2–3)*
Oral VKAtarget INR 2.5 (range 2–3)
Fuster et al. Circulation 2006; 2. Singer et al. Chest 2008*If mechanical valve, target INR 2.5
30Error bars = 95% CI; *Relative risk reduction for all strokes (ischaemic and haemorrhagic)
Warfarin reduces the risk of stroke in patients with AF
Relative risk reduction (%)*100 –10050 0 –50
AFASAK
SPAF
BAATAF
CAFA
SPINAF
EAFT
All trials
Warfarin better Placebo better
RRR = 64%95% CI: 49 to 74%
Hart RG et al. Ann Intern Med 2007;146:857–67
Warfarin vs Placebo
BMJ 2002;325:1022-5
22% (2% to 38%)
Reduction of Risk of Thromboembolism in Atrial Fibrillation
Aspirin vs Placebo
100 –10050 0 –50Aspirin better Aspirin worse
AFASAK I
SPAF I
EAFT
ESPS II
LASAF
UK-TIA
All trials (n=6)
Aspirin vs Clopidogrel + Aspirin
ACTIVE-A STUDY
N Engl J Med 2009;360;2066-78
0.4
0.3
0.2
0.1
00 1 2 3 4
Aspirin
Clopidogrel + AspirinCum
ulat
ive
Inci
denc
e
Years
0.4
0.3
0.2
0.1
00 1 2 3 4
Aspirin
Clopidogrel + AspirinCum
ulat
ive
Inci
denc
e
Years
STROKEPRIMARY OUTCOME
RR=0.72, p<0.001RR=0.89, p=0.01
Primary outcome : Stroke, MI, Non-CNS SystemicEmbolism or Death from Vascular Causes
Lancet 2006;367:1903-12
Years
STROKE
0.05
0.04
0.03
0.02
0.01
0
0 0.5 1.0 1.5
Clopidogrel+Aspirin
Warfarin
RR=1.72 (1.24-2.37), p=0.001
Cum
ulat
ive
haza
rd ra
tes
Years
Clopidogrel + Aspirin vs Warfarin
ACTIVE-W STUDY
0.10
0.8
0.6
0.4
0.2
0
0 0.5 1.0 1.5
Clopidogrel+Aspirin
Warfarin
RR=1.44 (1.18-1.76), p=0.0003
Cum
ulat
ive
haza
rd ra
tes
PRIMARY OUTCOME
34
Limitations of current Anticoagulants
• Vitamin K antagonists (VKAs) have greater efficacy butthe range of limitations make them challenging agents touse:1,2
– Narrow therapeutic window– Variable and unpredictable pharmacokinetics and pharma-
codynamics– Wide variety of drug–drug and drug–food interactions– Need for regular anticoagulation monitoring and dose
adjustments– Slow onset and offset of action
1. Turpie AG. Eur Heart J 2008;29:155–65;2. Khoo CW et al. Int J Clin Pract 2009;63:630–41
VKAs have a narrow therapeutic window
Fuster V et al. Circulation 2006;114:e257–e354
1International Normalized Ratio (INR)
Odd
s ra
tio
2
15
8
10
5
01
3 4 5 6 7
Therapeuticrange
20
Ischaemic strokeIschaemic stroke
Intracranial bleedingIntracranial bleeding
36
In the small proportion of patientswith AF receiving warfarin, the INR isoften outside the therapeutic range
No warfarin65%
INR above target6%
INR on target15%INR below target
13%
Samsa GP et al. Arch Intern Med 2000;160:967–73
Contraindications to VKA treatment
Coumadin: SmPC, 2009
Bleeding tendencies associated with active ulceration or overt bleeding:– Gastrointestinal, genitourinary or respiratory tracts– Cerebrovascular haemorrhage– Pericarditis and pericardial effusions– Cerebral aneurysms, dissecting aorta– Bacterial endocarditis
Haemorrhagic tendencies or blood dyscrasias– Thrombocytopaenia– Coagulation factor abnormalities
Recent or contemplated surgery of:– Central nervous system– Eye– Traumatic surgery resulting in large open surfaces
Severe hepatic or renal diseaseDiastolic blood pressure >110 mmHgPregnancyThreatened abortion
– Eclampsia– Preeclampsia
New oral anticoagulant agents• A number of novel anticoagulant agents have been developed,
targeting different components of the coagulation cascade
• Factor Xa inhibitors:– Direct: Rivaroxaban (phase III completed), Apixaban (phase III
completed), Edoxaban (phase III in development)– Indirect: idraparinux (Phase III trial terminated)
• Direct thrombin inhibitors– Ximelagatran: provided proof-of-concept but withdrawn from the
market in 2006 due to liver toxicity– AZD0837: Phase II completed– Dabigatran etexilate: Phase III completed
Rivaroxaban• Selective, direct Factor Xa
inhibitor1
• High oral bioavailability2
• Rapid onset of action3
• Half-life:2–4
– 7 – 11 hours• Dual mode of elimination:5
– 1/3 of active drug excretedunchanged by the kidneys
– 2/3 of drug metabolized by the liver;half of which is excreted renally,half excreted via thehepatobiliary route
1. Perzborn et al, 2005; 2. Kubitza et al, 2005a; 3. Kubitza et al, 2005b;4. Kubitza et al, 2008; 5. Weinz et al, 2009
Rivaroxaban
Xa
IIa
X IX
IXaVIIIa
Va
II
FibrinFibrinogen
Adapted fromWeitz et al, 2005; 2008
TF/VIIa
The promise of novel OACs
40
Improvedcompliance
Improvedefficacy
and safety
Less impact onpatient’s daily
life
ImprovedQoL
Less labour-intensive
Reducedadministrative
costs
Reduced potentialfor food and drug
interactions
1. Ansell J et al, 2004; 2. Mueck W et al, 2007; 3. Mueck W et al, 2008; 4. Mueck W et al, 2008;5. Raghavan N et al, 2009; 6. Shantsila E, Lip GY. 2008.
Simplified dosing regimen, no dietaryrestrictions, predictable anticoagulation
and no need for routine coagulationmonitoring.
Can be given at fixed doses
Rivaroxaban Once-daily oral direct factor Xa inhibition
Compared with vitamin K antagonism for prevention
of stroke and Embolism Trial in Atrial Fibrillation
42
Rivaroxaban Warfarin
Primary endpoint: stroke or non-CNS systemic embolism
INR target: 2.5(2.0–3.0 inclusive)
20 mg once daily(15 mg once daily
for CrCl 30–49 ml/min)
Atrial fibrillation
Randomizeddouble blind /
double dummy
Monthly monitoringAdherence to standard-of-care guidelines
ROCKET AF – study design
*Enrolment of patients without prior stroke, TIA or SE and only two factors capped at 10%
Risk factors• Stroke, TIA orsystemic embolus
OR• CHF• Hypertension• Age 75• Diabetes
At least 2or 3required*
Patel MR et al, 2010;
43
ROCKET AF – study endpointsPrimary efficacy endpoint• Composite of stroke and sytemic embolism (SE)
Secondary efficacy endpoints• Composite of stroke, SE and cardiovascular death• Composite of stroke, SE, cardiovascular death and MI• Individual components of the above endpoints
Principal safety endpoint• Composite of major and non-major clinically
relevant bleeding
Patel MR et al, 2011.
44
ROCKET AF – baseline characteristics (2)
CharacteristicRivaroxaban
(N=7,131)Warfarin(N=7,133)
CHADS2 score, mean ± SD 3.48±0.94 3.46±0.952, n (%) 925 (13.0) 934 (13.1)3, n (%) 3,058 (42.9) 3,158 (44.3)4, n (%) 2,092 (29.3) 1,999 (28.0)5, n (%) 932 (13.1) 881 (12.4)6, n (%) 123 (1.7) 159 (2.2)
Co-existing conditions, n (%)Previous stroke/TIA or SE 3,916 (54.9) 3,895 (54.6)Congestive heart failure 4,467 (62.6) 4,441 (62.3)Hypertension 6,436 (90.3) 6,474 (90.8)Diabetes mellitus 2,878 (40.4) 2,817 (39.5)Previous MI 1,182 (16.6) 1,286 (18.0)Peripheral vascular disease 401 (5.6) 438 (6.1)Chronic obstructive pulmonary disease 754 (10.6) 743 (10.4)
CrCl, median (25th, 75th), ml/min 67 (52, 88) 67 (52, 86)
ITT populationPatel MR et al, 2011.
45
Number of subjects at riskRivaroxaban 6,958 6,211 5,786 5,468 4,406 3,407 2,472 1,496Warfarin 7,004 6,327 5,911 5,542 4,461 3,478 2,539 1,538
ROCKET AF – primary efficacyendpoint
Per-protocol population – as treated
Warfarin
Rivaroxaban
Days since randomization
HR=0.79 (0.66, 0.96)p<0.001 (non-inferiority)
0 120 240 480 600 7200
1
2
3
4
5
6
840360
Cum
ulat
ive
even
t rat
e (%
)Stroke or systemic embolism
Patel MR et al, 2011.
46
ROCKET AF – primary efficacyendpoint components
Safety population – on-treatment analysis*Statistically significant
Favoursrivaroxaban
Favourswarfarin
Hazard ratioand 95% CIs
0.2 0.5 1 2 5
Endpoints
Rivaroxaban(N=7,061)
Warfarin(N=7,082)
Hazard ratio(95% CI)
n(% per year)
n(% per year)
Primary efficacy endpoint 189 (1.7) 243 (2.2) 0.79 (0.65, 0.95)*
All-cause stroke 184 (1.7) 221 (2.0) 0.85 (0.70,1.03)
Haemorrhagic stroke 29 (0.3) 50 (0.4) 0.59 (0.37,0.93)*
Ischaemic stroke 149 (1.3) 161 (1.4) 0.94 (0.75,1.17)
Unknown stroke type 7 (0.1) 11 (0.1) 0.65 (0.25,1.67)
Non-CNS SE 5 (0.04) 22 (0.2) 0.23 (0.09, 0.61)*
Patel MR et al, 2011.
Parameter
Rivaroxaban(N=7111)
Warfarin(N=7125) Hazard ratio
(95% CI)n (% per year) n (% per year)Principal safetyendpoint
1475 (14.9) 1449 (14.5) 1.03 (0.96,1.11)
Major bleeding 395 (3.6) 386 (3.4) 1.04 (0.90,1.20)
Hemoglobin drop2 g/dl)
305 (2.8) 254 (2.3) 1.22 (1.03,1.44)*
Transfusion 183 (1.6) 149 (1.3) 1.25 (1.01,1.55)*
Critical organbleeding
91 (0.8) 133 (1.2) 0.69 (0.53,0.91)*
Intracranialhemorrhage
55 (0.5) 84 (0.7) 0.67 (0.47,0.93)*
Fatal bleeding 27 (0.2) 55 (0.5) 0.50 (0.31,0.79)*
Non-major clinicallyrelevant bleeding
1185 (11.8) 1151 (11.4) 1.04 (0.96,1.13)
Safety population – as-treated analysis; *statistically significant
ROCKET AF – Bleeding Analysis
Major bleeding from gastrointestinal site (upper, lower and rectal):rivaroxaban = 224 events (3.2%); warfarin = 154 events (2.2%); p<0.001*
Hazard ratioand 95% CIs
0.2 0.5 1 2 5
Favorsrivaroxaban Favors
warfarinPatel et al. NEJM 2011, August 10th epub ahead of print
48
ROCKET AF – most frequenttreatment-emergent adverse events
Adverse event, no. (%)Rivaroxaban
(N=7,111)Warfarin(N=7,125)
Total patients with treatment-emergent AEs# 5,791 (81.4) 5,810 (81.5)Epistaxis* 721 (10.1) 609 (8.6)Peripheral oedema 435 (6.1) 444 (6.2)Dizziness 433 (6.1) 449 (6.3)Nasopharyngitis 421 (5.9) 455 (6.4)Cardiac failure 397 (5.6) 420 (5.9)Bronchitis 396 (5.6) 417 (5.9)Dyspnoea 380 (5.3) 394 (5.5)Diarrhoea 379 (5.3) 397 (5.6)Cough 343 (4.8) 353 (5.0)Back pain 338 (4.8) 347 (4.9)Upper respiratory tract infection 336 (4.7) 325 (4.6)Headache 324 (4.6) 363 (5.1)Arthralgia 301 (4.2) 331 (4.7)Haematuria* 296 (4.2) 242 (3.4)Urinary tract infection 293 (4.1) 321 (4.5)ALT >3× ULN and bilirubin >2× ULNeither on same day or within following 30 days
33 (0.5) 35 (0.5)
Safety population; *p<0.05. 15 most frequent based on rivaroxaban treatment arm.#Events that started on or after the first dose and up to 2 days after the last dose of study medication.
Patel MR et al, 2011. Slide notes contain data on file
49
ROCKET AF – all-cause mortality
Safety population – on-treatment analysis
Hazard ratioand 95% CIs
0.2 0.5 1 2 5Favours
rivaroxabanFavourswarfarin
Endpoints
Rivaroxaban(N=7,061)
Warfarin(N=7,082)
Hazard ratio(95% CI)
n(% per year)
n(% per year)
All-cause mortality 208 (1.9) 250 (2.2) 0.85 (0.70,1.02)
Vascular death 170 (1.5) 193 (1.7) 0.89 (0.73, 1.10)
Non-vascular death 21 (0.2) 34 (0.3) 0.63 (0.36, 1.08)
Unknown cause 17 (0.2) 23 (0.2) 0.75 (0.40, 1.41)
Patel MR et al, 2011.
50
ROCKET AF – conclusions• Based on the prespecified primary efficacy outcome:
– A once-daily fixed dose regimen of rivaroxaban was non-inferior towarfarin for prevention of stroke or non-CNS systemic embolism
• Safety:– Similar overall incidence of bleeding and adverse events– Increase in gastrointestinal bleeds but importantly fewer intracranial
haemorrhages and less fatal bleeding with rivaroxaban• Implication:
– Rivaroxaban, once approved in the indication, is a once-daily, provenalternative to warfarin with superior efficacy ‘on treatment’, similar overallbleeding and fewer intracranial haemorrhages
Conclusion:
• AF is a serious risk factor for Stroke• AF must be treated with anti platelet,
antithrombotic drug regardless to therisk level
• Currently some new oral antithromboticdrug are available.
• Rivaroxaban give a good promising inthe treatment of AF to prevent stroke.
Thank U
Atrial fibrillation is a commondisorder
• Approximately 1% of all people are affected by AF1
• Estimated prevalence rates for paroxysmal or persistent AF:2– Europe : 4.5 million USA : 2 million
• The lifetime risk of AF is almost one in four3
• The overall prevalence of AF is increasing, driven by:– Ageing of populations worldwide– Rising prevalence of chronic heart disease– Rising prevalence of AF risk factors, e.g. diabetes mellitus
• Hospital admissions for AF have increased by 60% over thepast 20 years4
1. Go AS et al. JAMA 2001;285:2370–5; 2. Fuster V et al. Circulation 2006;114:e257–354;3. Heeringa J et al. Eur Heart J 2006;27:949–53 4. Friberg J et al. Epidemiology 2003;14:666-72
Risk of major bleeding increases with theHAS-BLED score (p=0.007)
54
0
2
4
6
8
10
12
14
0 1 2 3 4 5 6 7 8 9
Ble
eds
per 1
00 p
atie
nt-y
ears
AF cohort of theEuro Heart Survey
HAS-BLED score
Pisters R et al, 2010.
Number ofpatients 798 1,286 744 187 46 8 2 0 0 0
Number ofbleeding events 9 13 14 7 4 1 0 0 0 0
Clinicalcharacteristic Points
Hypertension (SBP>160 mmHg) 1
Abnormal renal orliver function 1 + 1
Stroke 1Bleeding 1Labile INRs 1Elderly (age>65 years) 1
Drugs or alcohol 1 + 1Cumulative score Range 0 9
55
ROCKET AF – stroke outcomes
Endpoints
Rivaroxaban(N=7,061)
Warfarin(N=7,082)
Hazard ratio(95% CI)
n(% per year)
n(% per year)
Stroke 184 (1.7) 221 (2.0) 0.85 (0.70–1.03)
Stroke leadingto death*
47 (0.4) 67 (0.6) 0.71 (0.49–1.03)
Disabling* 43 (0.4) 57 (0.5) 0.77 (0.52–1.14)
Non-disabling* 88 (0.8) 87 (0.8) 1.03 (0.76–1.38)
Unknown 7 (0.1) 12 (0.1) 0.59 (0.23–1.50)
Safety population – on-treatment analysis*Based on investigator’s assessment of modified Rankin scale score:0–2=non-disabling, 3–5=disabling, and 6=death
Favoursrivaroxaban
Favourswarfarin
Hazard ratioand 95% CIs
0.2 0.5 1 2 5
Patel MR et al, 2011.
56
ROCKET AF – major bleeding by siteSite*
Rivaroxaban(N=7,111)
Warfarin(N=7,125)
Major bleeding, n (%) 395 (5.6) 386 (5.4)Gastrointestinal (upper, lower, rectal)# 224 (3.2) 154 (2.2)Intracranial‡ 55 (0.8) 84 (1.2)
Intraparenchymal‡ 37 (0.5) 56 (0.8)Non-traumatic‡ 33 (0.5) 54 (1.8)Traumatic 4 (0.1) 2 (0.03)
Intraventricular 2 (0.03) 4 (0.1)Subdural haematoma 12 (0.2) 22 (0.3)Subarachnoid 4 (0.1) 1 (0.01)Epidural haematoma 0 1 (0.01)
Macroscopic haematuria 26 (0.4) 21 (0.3)Bleeding associated with non-cardiac surgery 19 (0.3) 26 (0.4)Intraocular/retinal 17 (0.2) 24 (0.3)Intraarticular 16 (0.2) 21 (0.3)Epistaxis 13 (0.2) 14 (0.2)
*Site based on blinded adjudication.#Combined gastrointestinal bleed rate p<0.001; ‡p<0.05Patel MR et al, 2011.